ABSTRACT

Purpose: To develop a probability-based differential diagnosis for pediatric acute liver failure (PALF) based on age and socioeconomic status of the country of origin.

Methods: Comprehensive literature search using PubMed, EMBASE, and SCOPUS databases was performed. Children 0–22 years of age who met PALF registry criteria were included. Articles included >10 children, and could not be a case report, review article, or editorial. No language filter was utilized, but an English abstract was required. Etiology of PALF, age of child, and country of origin was extracted from included articles.

Results: 32 full text articles were reviewed in detail; 2,982 children were included. The top diagnosis of PALF in developed countries was acetaminophen toxicity (9.24%; 95% Credl 7.99–10.6), whereas in developing countries it was Hepatitis A (28.9%; 95% Credl 26.3–31.7). In developed countries, the leading diagnosis of PALF in children aged <1 year was metabolic disorder (17.2%; 95% Credl 10.3–25.5), whereas in developing countries it was unspecified infection (39.3%; Credl 27.6–51.8). In developed countries, the leading diagnosis in children aged >1 year was Non-A-B-C Hepatitis (8.18%; Credl 5.28–11.7), whereas in developing countries it was Hepatitis A (32.4%; Credl 28.6–36.3).

Conclusion: The leading causes of PALF in children aged 0-22 years differ depending on the age and developmental status of their country of origin, suggesting that these factors must be considered in the evaluation of children with PALF.

Keywords: Acute liver failure; Pediatric; Developed countries; Developing countries; Systematic review

INTRODUCTION

Pediatric acute liver failure (PALF) is a rapidly progressive syndrome in children that can lead to many devastating complications, such as renal and/or respiratory failure, hemodynamic instability, cerebral edema, sepsis, coagulopathy, and aplastic anemia [1-4]. The incidence of acute liver failure (ALF) across all age groups in the developed world is rare with an incidence of 10 cases per million. In the United States, it is estimated that 1,600 cases of ALF are reported each year [5]. In developing countries, the exact incidence of ALF is unknown, but estimated to be higher due to increased rates of hepatotropic infection [6].
The PALF registry developed criteria to classify PALF, which are distinct from those that define ALF in the adult population [7]. It is also important to distinguish PALF from acute liver injury in a child with pre-existing liver disease (i.e., acute on chronic liver failure) [8]. As such, the most updated definition of PALF requires the absence of identified pre-existing liver disease within the preceding 8 weeks of presentation, coagulopathy not corrected by administration of Vitamin K, evidence of hepatocellular injury, and either: international normalized ratio (INR) ≥1.5 with evidence of encephalopathy or INR ≥2.0 with or without evidence of encephalopathy [7].

It is estimated that 38 percent of cases of PALF have an unknown etiology, and the remaining causes of PALF can be classified as infectious, immunologic, metabolic, ischemic, and toxin- or drug-related, which differ depending on age group and geographic region [5]. The goal of this systematic review was to determine a probability-based differential diagnosis of the etiologies of PALF, taking into account the age of the child and expected variations related to geographic location.

**MATERIALS AND METHODS**

This systematic review followed The Preferred Reporting Items in Systematic Reviews and Meta-Analysis guidelines [9].

**Literature search**

A comprehensive literature search was performed using the PubMed, EMBASE, and SCOPUS databases. The search terms, “Acute Liver Failure” AND “Children” were input. Case reports, review articles, and studies including less than 10 children were excluded. In the SCOPUS search engine, the publication date was filtered to include only articles published in 2017, 2018, or 2019. No date filter was used in the PubMed or EMBASE databases. The aforementioned literature search was performed by two authors on two separate occasions (December 2018 and November 2019) to obtain the most complete review of the current literature. The bibliographies from each of the search engines were uploaded into the RefWorks program and exact duplicates were excluded automatically. The remaining articles were uploaded into Rayyan QCRI application [10]. In the Rayyan application, remaining duplicates were removed by hand and the abstracts were reviewed by two authors separately to include only those that met inclusion criteria (Table 1) [7]. Any conflicting decisions were resolved by a third author. Bibliographies of relevant review articles identified through the initial search were reviewed for studies that could qualify for this review. Full-text articles were reviewed for inclusion and exclusion.

**Table 1. Inclusion and exclusion criteria**

| I. Title contains “Acute Liver Failure” or “Acute Hepatic Failure” |
|---------------------------------------------------------------|
| II. Minimum number of studied children is 10                  |
| III. Children are age 0–22 years old                         |
| IV. Diagnosis of PALF was made according to the PALF registry criteria [7] |
| V. Study entry criteria requires review of all children with ALF without another co-existing diagnosis or treatment modality. For example, studies that examined the etiology of acute liver failure from only children with known metabolic diseases were excluded. Studies that examined the etiology of acute liver failure from only children who underwent liver transplant were excluded. |
| VI. Not a case report                                         |
| VII. Not a review article                                     |
| VIII. Not an editorial                                        |
| IX. No language filter was utilized, but an English abstract was required |

PALF: pediatric acute liver failure, ALF: acute liver failure.
exclusion criteria. When articles used the same or mostly overlapping cohort of children in their analysis, only the most recently published article was included.

**Data extraction**

The selected articles were read individually, and data from each was extracted into Google spreadsheets. The country of origin for each study was identified and countries were divided into “developed” and “developing” categories as identified by the United Nations [11,12]. Etiologies of PALF and number of children affected with each were recorded. When possible, specific ages of the patients were recorded. For missing or unclear data, we contacted the authors of the articles by email.

**Data analysis**

A Bayesian methodology was employed to determine the rate estimates and the associated 95% credible intervals for each disease entity; the beta distribution was used as the conjugate prior to the conditional likelihood distribution for each rate estimate determined from the extracted data [11,13].

**RESULTS**

Fig. 1 outlines the results of the systematic review. The database searches provided a total of 1,152 results (PubMed- 778 articles, EMBASE- 283 articles, Scopus- 91 articles). In addition, bibliography reviews provided 2 more studies.
After exact duplicates were removed, abstracts of 675 articles were reviewed. After exclusion of abstracts that did not meet inclusion criteria (Table 1) [7], a total of 75 full-text articles were examined in detail. Forty-three full text articles were excluded: 16 did not utilize PALF criteria, 8 were oral presentations without full length transcripts (including abstracts presented at conferences), 8 utilized data from the same or mostly overlapping cohort of patients, 7 examined sub-populations (ex, children receiving liver transplants), 2 were editorials, and 2 did not differentiate between adults and children in their data reports.

A total of 32 articles (published between 1997–2019) met inclusion criteria and were analyzed for this study. Table 2 [14-45] summarizes the data extracted from these studies. A total of 2,989 subjects were included in our analysis (2,019 from developed countries and 970 from developing countries), with an age range of 0–22 years old.

Table 3 shows the most common diagnoses of PALF in both developed and developing countries. Of the 2,019 children in developed countries, the most frequent cause of PALF was acetaminophen toxicity (9.24%; 95% CredI 7.99–10.6), followed by unspecified metabolic disorders (5.47%; 95% CredI 4.5–6.52), and unspecified infection (5.06%; 95% CredI 4.13–6.08). 39.7% (95% CredI 37.6–41.9) of the causes were of indeterminate origin. Of the 970 children in developing countries, the most frequent cause of PALF was Hepatitis A (28.9%;

| First author | Year published | Study design | Country | Economic status | No. of patients | Percentage of total patients (%)* |
|--------------|----------------|-------------|---------|----------------|----------------|----------------------------------|
| Alam [14]    | 2015           | Retrospective | India   | Developing     | 30             | 1.0                              |
| Alam [15]    | 2016           | Prospective  | India   | Developing     | 33             | 1.1                              |
| Baris [16]   | 2012           | Retrospective | Turkey  | Developing     | 74             | 2.5                              |
| Bersani [17] | 2019           | Retrospective | Italy   | Developed      | 10             | 0.3                              |
| Brett [18]   | 2013           | Retrospective | Portugal | Developed    | 28             | 0.9                              |
| Chongsrisawat [19] | 2009       | Retrospective | Thailand | Developing   | 53             | 1.8                              |
| De Giorgio [20]    | 2019          | Retrospective | Italy   | Developed      | 56             | 1.9                              |
| Di Giorgio [21]    | 2017          | Retrospective | Italy   | Developed      | 55             | 1.8                              |
| Gilbert Perez [22] | 2018        | Retrospective | Spain   | Developed      | 49             | 1.6                              |
| Grama [23]   | 2019           | Retrospective | Romania | Developing     | 97             | 3.2                              |
| Hegarty [24] | 2013           | Retrospective | UK      | Developed      | 127            | 4.2                              |
| Karethmann [25] | 2015         | Retrospective | Germany | Developed      | 37             | 1.2                              |
| Kaur [26]    | 2013           | Prospective  | India   | Developing     | 43             | 1.4                              |
| Lee [27]     | 2018           | Retrospective | Argentina | Developing   | 210            | 7.0                              |
| Lu [28]      | 2009           | Prospective  | USA     | Developed      | 53             | 1.8                              |
| Mazumder [29] | 2016          | Retrospective | Bangladesh | Developing | 62             | 0.2                              |
| Mckiernan [30] | 2016         | Retrospective | UK      | Developed      | 39             | 1.3                              |
| Mustafa [31] | 2009           | Retrospective | UK      | Developed      | 56             | 1.9                              |
| Narkewicz [32] | 2018         | Prospective  | USA and UK | Developed  | 1,144         | 38.3                             |
| Ng [33]      | 2016           | Retrospective and prospective | Malaysia | Developing | 60             | 2.0                              |
| Nunez-Ramos [34] | 2018         | Retrospective | Spain   | Developed      | 20             | 0.1                              |
| Oh [35]      | 2016           | Retrospective | Korea   | Developed      | 126            | 4.2                              |
| Ozcay [36]   | 2011           | Retrospective | Turkey  | Developing     | 67             | 2.2                              |
| Ozcay [37]   | 2016           | Retrospective | Turkey  | Developing     | 91             | 3.0                              |
| Rajanayagam [38] | 2013         | Retrospective | Australia | Developed   | 54             | 1.8                              |
| Rivera-Penera [39] | 1997        | Retrospective | USA     | Developed      | 66             | 2.2                              |
| Sanchez [40] | 2016           | Retrospective | Argentina | Developing   | 57             | 1.9                              |
| Sanchez [41] | 2012           | Retrospective | Argentina | Developing   | 40             | 1.3                              |
| Silverio [42] | 2015          | Prospective  | Cuba    | Developing     | 31             | 1.0                              |
| Tung [43]    | 2000           | Retrospective | London  | Developed      | 75             | 2.5                              |
| Wands [44]   | 2018           | Retrospective | Scotland | Developed   | 24             | 0.8                              |
| Yankol [45]  | 2016           | Retrospective | Turkey  | Developing     | 22             | 0.7                              |

*Rounded to nearest 0.1%.
Differential Diagnosis of Acute Liver Failure in Children

Table 3. Etiology of PALF in children 0-22 years old in developed and developing countries

| Etiology* | Developed (n=2,019) | Mean | 95% credible interval | Etiology† | Developing (n=970) | Mean | 95% credible interval |
|-----------|---------------------|------|-----------------------|-----------|-------------------|------|---------------------|
|           |                     |      | Lower                 |           |                   |      | Lower               |
| Indeterminate | 770                 | 39.7 | 37.6–41.9             | Hepatitis A | 316               | 28.9 | 26.3–31.7           |
| Acetaminophen toxicity | 179 | 9.24 | 7.99–10.6 | Indeterminate | 220 | 20.1 | 17.8–22.6 |
| Unspecified metabolic disorder | 106 | 5.47 | 4.5–6.52 | Unspecified infection | 104 | 9.52 | 7.86–11.3 |
| Unspecified infection | 98 | 5.06 | 4.13–6.08 | Wilson's disease | 85 | 7.78 | 6.27–9.44 |
| Other | 79 | 4.08 | 3.24–5 | Autoimmune disorder | 48 | 4.4 | 3.26–5.69 |
| Ischemia | 67 | 3.46 | 2.69–4.31 | Unspecified toxin | 30 | 2.75 | 1.86–3.8 |
| Unspecified toxin | 64 | 3.3 | 2.55–4.14 | Dengue virus | 29 | 2.66 | 1.79–3.69 |
| Hemophagocytic lymphohistiocytosis | 55 | 2.84 | 2.15–3.62 | Unspecified metabolic disorder | 29 | 2.66 | 1.79–3.69 |
| Herpes simplex virus-enterovirus co-infection | 53 | 2.73 | 2.06–3.51 | Hemophagocytic lymphohistiocytosis | 28 | 2.56 | 1.71–3.58 |
| Wilson's disease | 51 | 2.63 | 1.97–3.39 | Acetaminophen toxicity | 27 | 2.47 | 1.64–3.47 |
| Congenital heart disease | 43 | 2.22 | 1.61–2.92 | Mushroom toxicity | 19 | 1.74 | 1.05–2.6 |
| Galactosemia | 39 | 2.01 | 1.44–2.68 | Hepatitis B | 11 | 1.01 | 0.504–1.68 |
| Hemochromatosis | 31 | 1.6 | 1.09–2.2 | Galactosemia | 11 | 1.01 | 0.504–1.68 |
| Autoimmune disorder | 30 | 1.55 | 1.05–2.31 | Albendazole toxicity | 11 | 1.01 | 0.504–1.98 |
| Non-A-B-C hepatitis | 23 | 1.19 | 0.754–1.71 | | | | |
| Herpes simplex virus | 23 | 1.19 | 0.754–1.71 | | | | |
| Unspecified mitochondrial disorder | 21 | 1.08 | 0.672–1.59 | | | | |

PALF: pediatric acute liver failure.
*Etiologies of PALF in developed countries that accounted for less than 1% of diagnoses include: Hepatitis A, Myelodysplastic syndrome, Mushroom toxicity, Mitochondrial respiratory deficiency, Ornithine transcarboxylase deficiency, Respiratory failure, Hypoxia, Fetal distress, Enterovirus, Autoimmune hepatitis type 1 & 2, Leukemia, Tyrosinemia type I, Hematologic/oncologic cause, Hepatitis E, Solid tumor, Gastrointestinal anomaly, Adenovirus, Veno-occlusive disease, Congenital diaphragmatic hernia, Hepatitis B, Parovirus B19, Influenza, Defect in glycosylation, Niemann pick C, Human herpes virus 6, Hyperornithinemia-homocitrullinemia syndrome, Isoniazid toxicity, Lamotrigine toxicity, Gestational alloimmune disease, Chemotherapy, Hodgkins lymphoma, Recurrent acute liver failure.
†Etiologies of PALF in developing countries that accounted for less than 1% of diagnoses include: Non A-G Hep, Cytomegalovirus, Epstein-barr virus, Tyrosinemia 1, Ischemia/hypoxia hemochromatosis, Autoimmune hepatitis type 1 & 2, Sepsis, Fatty acid oxidation defect, Hepatitis E, Herpes simplex virus, Fructose intolerance, Carnitine palmitoyltransferase 1 deficiency, Isoniazid toxicity, Phosphorous ingestion, Mitochondrial disorder, Hepatitis A virus-Hepatitis E virus coinfection, Varicella zoster virus, Urea cycle defect, Reyes syndrome, Firework toxicity, Lymphoma, Cardiomyopathy, Congenital hypopituitarism.

95% CredI 26.3–31.7), followed by unspecified infection (9.52%; 95% CredI 7.86–11.3) and Wilson’s disease (7.78%; 95% CredI 6.27–9.44). 20.1% (95% CredI 17.8–22.6) of cases were of indeterminate origin.

Table 4 provides a detailed view of the etiologies of PALF in children in developing countries. Studies that were included in Table 4 clearly distinguished both the age of the child and diagnosis; all other studies from developing countries were excluded. This resulted in a total of 61 children under the age of 1 year and 562 children over the age of 1 year. Of the 61 children under 1 year of age, the most common etiology was unspecified infection (39.3%; 95% CredI 27.6–51.8), followed by cytomegalovirus infection (13.1%; 95% CredI 5.94–22.6), and metabolic disorder (4.92%; 95% CredI 1.04–11.5). Of the 562 children over 1 year old, the most common etiology was Hepatitis A (32.4%; 95% CredI 28.6–36.3), followed by unspecified infection (14.9%; 95% CredI 12.1–18.0), and autoimmune disorders (3.56%; 95% CredI 2.19–5.24). 18% (95% CredI 14.9–21.2) of cases were of indeterminate origin.

Table 5 provides a detailed view of the etiologies of PALF in children in developed countries. Studies that were included in Table 5 clearly distinguished both the age of the child and diagnosis; all other studies from developed countries were excluded. This resulted in a total of 93 children under the age of 1 year and 281 children over the age of 1 year. Of the 93 children under 1 year of age, the most common etiology was a metabolic disorder (17.2%; 95% CredI 10.3–25.5), followed by ischemia (14%; 95% CredI 7.74–21.7) and hemochromatosis (12.9%; 95% CredI 6.93–20.4). 15.1% (95% CredI 8.58–23.0) of cases
Table 4. Etiology of palf in developing countries

| Etiology                              | <1-year-old (n=61) | Mean 95% credible interval | Etiology* | 1–21 years old (n=562) | Mean 95% credible interval |
|---------------------------------------|--------------------|-----------------------------|-----------|-------------------------|----------------------------|
|                                       |                    | Lower          | Upper     | Lower          | Upper                     |
| Unspecified infection                 | 24                 | 39.3           | 27.6      | 51.8           | Hepatitis A               | 182                       | 32.4                       | 28.6                       | 36.3                       |
| Cytomegalovirus                      | 8                  | 13.1           | 5.94      | 22.6           | Indeterminate             | 101                       | 18                         | 14.9                       | 21.2                       |
| Metabolic disorder                   | 3                  | 4.92           | 1.04      | 11.5           | Unspecified infection     | 84                        | 14.9                       | 12.1                       | 18                         |
| Hemochromatosis                      | 2                  | 3.28           | 0.406     | 8.94           | Autoimmune disorder       | 20                        | 3.56                       | 2.19                       | 5.24                       |
| Galactosemia                          | 2                  | 3.28           | 0.406     | 8.94           | Unspecified tox           | 19                        | 3.38                       | 2.05                       | 5.02                       |
| Congenital hypopituitarism            | 2                  | 3.28           | 0.406     | 8.94           | Acetaminophen toxicity    | 18                        | 3.2                        | 1.91                       | 4.81                       |
| Herpes simplex virus                 | 1                  | 1.64           | 0.0422    | 5.96           | Mushroom toxicity         | 14                        | 2.49                       | 1.37                       | 3.93                       |
| Klebsiella                            | 1                  | 1.64           | 0.0422    | 5.96           | Albenzadole toxicity      | 11                        | 1.96                       | 0.983                      | 3.25                       |
| Hemophagocytic lymphohistocytosis     | 1                  | 1.64           | 0.0422    | 5.96           | Non-A-G hepatitis         | 9                         | 1.6                        | 0.736                      | 2.79                       |
| Fructose intolerance                 | 1                  | 1.64           | 0.0422    | 5.96           | Epstein barr virus        | 7                         | 1.25                       | 0.503                      | 2.31                       |
| Pyruvate carboxylase deficiency       | 1                  | 1.64           | 0.0422    | 5.96           | Hemophagocytic lymphohistocytosis | 6                  | 1.07                       | 0.393                      | 2.07                       |

PABL: pediatric acute liver failure.

*Etiologies of PABL in children >1 year old that accounted for less than 1% of the diagnoses include: Hepatitis B, Galactosemia, Fatty acid oxidation defect, Carnitine palmitoyltransferase i deficiency, Isorniazid toxicity, Hepatitis C, Herpes simplex virus, Phosphorous ingestion, Firework ingestion, Ischeimia/hypoxia, Cardiomyopathy, Hepatitis E, Hepatitis A+Hepatitis B co-infection, Non-ABC hepatitis, Adenovirus, Dengue virus, Salmonella, Wilson's disease+Hepatitis A, Wilson's disease+Hepatitis E, Hemochromatosis, Niemann pick disease, Wolman's syndrome, Alpers syndrome, Unspecified metabolic disorder, Valproate toxicity, Reye's syndrome, Fluconazole toxicity, Indomethacin toxicity, Isoflurane+Leufunomide toxicity, Meropenem+Isoniazid+Rifampin+Pyrazinamide toxicity, Diphenylhydantoin/phenytoin toxicity, and Non-hodgkin lymphoma.

Table 5. Etiology of palf in developed countries

| Etiology                              | <1-year-old (n=93) | Mean 95% credible interval | Etiology* | 1–22 years old (n=281) | Mean 95% credible interval |
|---------------------------------------|--------------------|-----------------------------|-----------|-------------------------|----------------------------|
|                                       |                    | Lower          | Upper     | Lower          | Upper                     |
| Metabolic disorder                   | 16                 | 17.2           | 10.3      | 25.5           | Indeterminate             | 80                        | 28.5                       | 23.4                       | 33.9                       |
| Indeterminate                        | 14                 | 15.1           | 8.58      | 23.0           | Non-A-B-C hepatitis       | 23                        | 8.19                       | 5.28                       | 11.7                       |
| Ischemia                              | 13                 | 14             | 7.74      | 21.7           | Acetaminophen toxicity    | 22                        | 7.83                       | 4.99                       | 11.2                       |
| Hemochromatosis                      | 12                 | 12             | 6.93      | 20.4           | Autoimmune disorder       | 21                        | 7.47                       | 4.7                        | 10.8                       |
| Herpes simplex virus                 | 9                  | 9.68           | 4.57      | 16.4           | Wilson's disease          | 18                        | 6.41                       | 3.85                       | 9.54                       |
| Hypoxia                              | 8                  | 8.6            | 3.83      | 15.1           | Unspecified tox           | 18                        | 6.41                       | 3.85                       | 9.54                       |
| Hepatitis E                          | 5                  | 5.38           | 1.79      | 10.8           | Metabolic disorder        | 17                        | 6.05                       | 3.58                       | 9.11                       |
| Enterovirus                          | 4                  | 4.3            | 1.2       | 9.23           | Hepatitis A               | 13                        | 4.63                       | 2.49                       | 7.37                       |
| Hemophagocytic lymphohistocytosis     | 3                  | 3.23           | 0.678     | 7.63           | Hemophagocytic lymphohistocytosis | 8                  | 2.85                       | 1.24                       | 5.08                       |
| Cytomegalovirus                      | 2                  | 2.15           | 0.264     | 5.91           | Mushroom toxicity         | 8                         | 2.85                       | 1.24                       | 5.08                       |
| Galactosemia                          | 2                  | 2.15           | 0.264     | 5.91           | Autoimmune hepatitis type 1 | 7                         | 2.49                       | 1.01                       | 4.61                       |
| Mitochondrial respiratory deficiency | 2                  | 2.15           | 0.264     | 5.91           | Autoimmune hepatitis type 2 | 7                         | 2.49                       | 1.01                       | 4.61                       |
| Myelodysplastic syndrome              | 2                  | 2.15           | 0.264     | 5.91           | Hepatitis B               | 3                         | 1.07                       | 0.222                      | 2.56                       |
| Gestational alloimmune liver disease | 1                  | 1.08           | 3.93      | 0.028          | Parvovirus B19            | 3                         | 1.07                       | 0.222                      | 2.56                       |
|                                       |                    |                |           |                | Influenza                 |                           |                            |                            |                            |
|                                       |                    |                |           |                | Veno-occlusive disease    |                           |                            |                            |                            |

PABL: pediatric acute liver failure.

*Etiologies of PABL in children >1 year old that accounted for less than 1% of the diagnoses include: Unspecified infection, Ornithine transcarbamylase deficiency, Hyperornithinemia- hyperammonemia-homocitrullinemia syndrome, Isoniazid toxicity, Mitochondrial disorder, Hodgkins lymphoma, Herpes simplex virus, Human herpes virus-6, Epstein-barr virus, Echovirus, Parainfluenza, Hemochromatosis, Galactosemia, Glycogen storage disease, Fatty acid oxidation disorder, Valproate toxicity, Lamotrigine toxicity, Carbamazepine toxicity, Non-steroidal inflammatory drug toxicity, Mitochondrial respiratory deficiency, Reye's syndrome.

The etiology of acute liver failure in children was most commonly attributable to Hepatitis A (8.19%; 95% Cred 5.28–11.7), followed by acetyaminophen toxicity (7.83%; 95% Cred 4.99–11.2) and autoimmune disorders (7.47%; 95% Cred 4.7–10.8). 28.5% (95% Cred 23.4–33.9) of cases were of indeterminate origin.
DISCUSSION

Comprehensive review of PALF literature between 1997-2019 yielded 32 full text articles for a sum of 2,989 children that were included in this systematic review. These children originated from both developed and developing countries and spanned the age range of 0–22 years old. Results demonstrate that developmental status of the country and age of the child are important determinants of the etiologies of PALF.

The top three diagnoses of PALF in developing countries were: Hepatitis A infection (28.9%; 95% CredI 26.3–31.7), unspecified infection (9.52%; 95% CredI, 7.86–11.3), and Wilson’s disease (7.78%; 95% CredI 6.27–9.44), whereas in developed countries the top three most common diagnoses were acetaminophen toxicity (9.24%; 95% CredI 7.99–10.6), unspecified metabolic disorder (5.47%; 95% CredI 4.5–6.52), and unspecified infections (5.06%; 95% CredI 4.13–6.08). Children under 1 year old in developed countries were most commonly diagnosed with an unspecified metabolic disorder (17.2%; 95% CredI 10.3–25.5), whereas children under 1 year old in developing countries were most commonly diagnosed with an unspecified infectious etiology (39.3%; 95% CredI 27.6–51.8). Children greater than 1 year old in developed countries with PALF were most commonly diagnosed with non-A-B-C hepatitis (8.19%; 95% CredI 5.28–11.7) whereas in developing countries Hepatitis A infection (32.4%; 95% CredI 28.6–36.3) was the most common diagnosis.

Clearly, the frequencies in etiologies of PALF differ between developed and developing countries, and as such it is an important factor to consider in the diagnosis of PALF. In both developed and developing countries, stratification of the data by age range also yields different frequencies of the etiologies of PALF. While some of the discrepancy in frequencies according to age group may be attributed to exclusion of articles that did not specify the ages of their children, it also highlights the importance of taking a child’s age into account when approaching a patient with PALF.

The etiologies of PALF and their relative frequencies listed in the present review differ from previous analyses. In a review by Squires et al. [46,47], acetaminophen toxicity was found to be the most common etiology of PALF in all children 0–18 years. The cohort of children in this analysis originated solely from developed countries and was substantially smaller than the population of children in the present study. In another review of PALF, Dhawan lists metabolic etiologies as the most common cause of PALF in North America and Europe, and Hepatitis A as the most common etiology in Asia and South America [48]. Neither of these studies were systematic reviews. The study presented here categorized data by developed and developing countries and found Hepatitis A to be the leading cause of PALF in developing countries, while acetaminophen toxicity was the leading cause in developed countries.

Limitations

As a systematic review, this article has inherent limitations. The etiologies of PALF listed in the articles utilized for this study were taken at face value (as reported by their respective studies), resulting in vague etiologies such as non-A-B-C Hepatitis and unspecified infection. Available diagnostic resources, criteria, and rigor of evaluation were not standardized across institutions, accounting, in part, for the large number of indeterminate or unspecified etiologies of PALF and raising issues about diagnostic consistency. Age categories were established with the goal of including as many patients as possible in each category. While efforts were made to contact authors regarding age distributions, many studies did not include this information and were excluded from age analysis, resulting in a smaller sample...
size in Tables 4 and 5 compared to Tables 3 and 4. Unfortunately, most of the studies that did provide age ranges reported those ranges as 0–1 year old and >1 year old. As such, the age category of 1–22 years was unable to be narrowed because specific ages for children in that category were mostly unavailable. One other consequence of this issue was the fact that 90% of children aged 0–1 in developed countries were 0 to 28 days of age. This highlights the need for future studies to report the ages of their patients more specifically, so that the differential diagnosis for PALF can be narrowed according to the child’s age category.

Conclusion
In summary, the leading causes of PALF in children aged 0–22 years in developed and developing countries were different. Moreover, sub-analysis of these children by age yielded distinct etiologies, suggesting that both the age of the child and socioeconomic status of the child’s country of origin need to be considered in the evaluation of children with PALF. Future studies need to be prospective and geographically diverse; clinical evaluations need to be complete and consistent, while diagnostic criteria need to be strict and well-defined.

ACKNOWLEDGEMENTS
We would like to thank Dr. Robert Squires (University of Pittsburgh Medical Center, Pittsburgh, PA, USA) and Dr. Angelo Di Giorgio (Ospedale Papa Giovanni XXIII, Bergamo, Italy) for providing us with further information about their study population and results.

REFERENCES

1. Devictor D, Tissieres P, Durand P, Chevret L, Debray D. Acute liver failure in neonates, infants and children. Expert Rev Gastroenterol Hepatol 2011;5:717-29. PUBMED | CROSSREF
2. Hadzić N, Height S, Ball S, Rela M, Heaton ND, Vey P, et al. Evolution in the management of acute liver failure-associated aplastic anaemia in children: a single centre experience. J Hepatol 2008;48:68-73. PUBMED | CROSSREF
3. Yan J, Li S, Li S. The role of the liver in sepsis. Int Rev Immunol 2014;33:498-510. PUBMED | CROSSREF
4. Bhatia V, Lodha R. Intensive care management of children with acute liver failure. Indian J Pediatr 2010;77:1288-95. PUBMED | CROSSREF
5. Bower WA, Johns M, Margolis HS, Williams IT, Bell BP. Population-based surveillance for acute liver failure. Am J Gastroenterol 2007;102:2459-63. PUBMED | CROSSREF
6. Bernal W, Auzinger G, Dhawan A, Wendon J. Acute liver failure. Lancet 2010;376:190-201. PUBMED | CROSSREF
7. James LP, Alonso EM, Hynan LS, Hinson JA, Davern TJ, Lee WM, et al. Detection of acetaminophen protein adducts in children with acute liver failure of indeterminate cause. Pediatrics 2006;118:e676-81. PUBMED | CROSSREF
8. Schattenberg JM, Galle PR, Schuchmann M. [Acute liver failure--medical viewpoints]. Praxis (Bern 1994) 2006;95:1873-7. German. PUBMED | CROSSREF
9. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097. PUBMED | CROSSREF
10. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev 2016;5:210. PUBMED | CROSSREF
11. Kruschke JK. Inferring a binomial proportion via exact mathematical analysis. In: Kruschke JK, ed. Doing Bayesian data analysis: a tutorial with R and BUGS. Burlington: Academic Press, 2011.
12. Hongbo W, Kirui M, Lopes C, Alkalai S, Barcena A, Heyzer N, et al. World Economic Situation and Prospects 2014 [Internet]. New York: United Nations; 2014 May 21 [cited 2020 Jan 24]. Available from: http://www.un.org/en/development/desa/policy/wesp/index.shtml
13. Davitt M, Delvecchio MT, Aronoff SC. The differential diagnosis of vertigo in children: a systematic review of 2736 cases. Pediatr Emerg Care 2020;36:368-71.
14. Alam S, Lal BB, Khanna R, Sood V, Rawat D. Acute liver failure in infants and young children in a specialized pediatric liver centre in India. Indian J Pediatr 2015;82:879-83.
15. Sood V, Rawat D, Khanna R, Sharma S, Gupta PK, Alam S, et al. Study of prevalence of fatty acid oxidation defects in children and adults with acute liver failure: significance of carnitine/acylcarnitine and aminoacid profile. J Clin Exp Hepatol 2016;6 Suppl 1:S1.
16. Barış Z, Salıtk Temizel İN, Uslu N, Usta Y, Demir H, Gürakan F, et al. Acute liver failure in children: 20-year experience. Turk J Gastroenterol 2012;23:127-34.
17. Bersani I, Auriti C, Piersigilli F, Dotta A, Di Pede A, et al. Neonatal acute liver failure due to enteroviruses: a 14 years single NICU experience. J Matern Fetal Neonatal Med 2020;33:2576-80.
18. Brett A, Pinto C, Carvalho L, Garcia P, Diogo L, Gonçalves I. Acute liver failure in under two year-olds--are there markers of metabolic disease on admission? Ann Hepatol 2013;12:791-6.
19. Chongsrisawat V, Hutagalung V, Poovorawan Y. Liver function test results and outcomes in children with acute liver failure due to dengue infection. Southeast Asian J Trop Med Public Health 2009;40:47-53.
20. Di Giorgio A, Nicastro E, Dalla Rosa D, Nebbia G, Sonzogni A, D’Antiga L. Transplant-free survival in chronic liver disease presenting as acute liver failure in childhood. Transplantation 2019;103:544-51.
21. Di Giorgio A, Sonzogni A, Picciché A, Alessio G, Bonanomi E, Colledd M, et al. Successful management of acute liver failure in Italian children: a 16-year experience at a referral centre for paediatric liver transplantation. Dig Liver Dis 2017;49:1139-45.
22. Gilbert Pérez JJ, Jordano Moreno B, Rodriguez Salas M. [Aetiology, outcomes and prognostic indicators of paediatric acute liver failure]. An Pediatr (Barc) 2018;88:63-8. Spanish.
23. Grama A, Burac L, Cainap SS, Aldea C, Delean D, Bulata B, et al. OCS0 Acute liver failure in children: aetiology and evolution. Arch Dis Child 2019;104:A21.
24. Hegarty R, Dhanaw A, Gissen P. PG82 Study of acute liver failure in newborns and young children with an underlying inherited metabolic disease. Arch Dis Child 2013;98 Suppl 1:A41.
25. Kathemann S, Bechmann LP, Sowa JP, Manka P, Dechène A, Gerner P, et al. Etiology, outcome and prognostic factors of childhood acute liver failure in a German single center. Ann Hepatol 2015;14:722-8.
26. Kaur S, Kumar P, Kumar V, Sarin SK, Kumar A. Etiology and prognostic factors of acute liver failure in children. Indian Pediatr 2013;50:677-9.
27. Lee EJ, Ko JS, Moon JS, Kim JW. Prognostic factors in paediatric acute liver failure. J Pediatr Gastroenterol Nutr 2018;66 Suppl 2:856.
28. Lu BR, Gralla J, Liu E, Dobyns EL, Narkewicz MR, Sokol RJ. Evaluation of a scoring system for assessing prognosis in pediatric acute liver failure. Clin Gastroenterol Hepatol 2008;6:1140-5.
29. Mazumder MW, Karim AB, Rukunuzzaman M, Rahman MA. Aetiology and outcome of acute liver failure in children: experience at a tertiary care hospital of Bangladesh. Mymensingh Med J 2016;25:492-4.

https://doi.org/10.5223/pghn.2020.23.6.501
30. McKiernan P, Ball S, Santra S, Foster K, Fratter C, Poulton J, et al. Incidence of primary mitochondrial disease in children younger than 2 years presenting with acute liver failure. J Pediatr Gastroenterol Nutr 2016;63:592-7.
PUBMED | CROSSREF

31. Mustafa A, Mitry R, Ngjanga-Bakwin K, Hussain M, Dhawan A. Mechanisms of hepatocellular death in acute liver failure of indeterminate aetiology in children. Liver Transpl 2009;15(7 Suppl):S102.
CROSSREF

32. Narkiewicz MR, Horslen S, Hardison RM, Shneider BL, Rodriguez-Baez N, Alonso EM, et al. A learning collaborative approach increases specificity of diagnosis of acute liver failure in pediatric patients. Clin Gastroenterol Hepatol 2018;16:1801-10.e3.
PUBMED | CROSSREF

33. Ng RT, Lee WS, Ong SY, Foo HW. Acute liver failure in Malaysian children. J Pediatr Gastroenterol Nutr 2016;63 Suppl 2:S343.
CROSSREF

34. Núñez-Ramos R, Montoro S, Bellusci M, Del Fresno-Valencia MB, Germán-Díaz M, Urruzuno P, et al. Acute liver failure: outcome and value of pediatric end-stage liver disease score in pediatric cases. Pediatr Emerg Care 2018;34:409-12.
PUBMED | CROSSREF

35. Oh SH, Jeong I, Namgoong JM, Kim DY, Kim KM. Causes and outcomes of young children with acute liver failure in a single center. Transplantation 2016;100(5 Suppl):S165-6.
CROSSREF

36. Ozcay F, Hosnut FO, Canan O, Oncel EK, Karakayali H, Moray G, et al. Acute liver failure in Turkish children: etiology, prognostic factors, and outcome. Pediatr Transplant 2011;15 Suppl 1:49.
CROSSREF

37. Özçay F, Karadağ Öncel E, Barış Z, Canan O, Moray G, Haberal M. Etiologies, outcomes, and prognostic factors of pediatric acute liver failure: a single center's experience in Turkey. Turk J Gastroenterol 2016;27:450-7.
PUBMED | CROSSREF

38. Rajanayagam J, Coman D, Cartwright D, Lewindon PJ. Pediatric acute liver failure: etiology, outcomes, and the role of serial pediatric end-stage liver disease scores. Pediatr Transplant 2013;17:362-8.
PUBMED | CROSSREF

39. Rivera-Penera T, Moreno J, Skaff C, McDiarmid S, Vargas J, Ament ME. Delayed encephalopathy in fulminant hepatic failure in the pediatric population and the role of liver transplantation. J Pediatr Gastroenterol Nutr 1997;24:128-34.
PUBMED | CROSSREF

40. Sanchez MC, Cavalieri ML, Soledad MM, Gustavo B, Victoria FDC, Orsi M, et al. Different etiologies with variable prognosis in children with acute liver failure in a single center in Argentina: PELD performance as a prognostic marker. J Pediatr Gastroenterol Nutr 2016;63 Suppl 2:S126-7.
CROSSREF

41. Sanchez MC, D’Agostino DE. Pediatric end-stage liver disease score in acute liver failure to assess poor prognosis. J Pediatr Gastroenterol Nutr 2012;54:193-6.
PUBMED | CROSSREF

42. Silverio CE, Smithen-Romany CY, Hondal NI, Diaz HO, Castellanos MI, Sosa O. Acute liver failure in Cuban children. MEDICC Rev 2015;17:48-54.
PUBMED | CROSSREF

43. Tung J, Haidzic N, Layton M, Baker AJ, Dhawan A, Rela M, et al. Bone marrow failure in children with acute liver failure. J Pediatr Gastroenterol Nutr 2000;31:557-61.
PUBMED | CROSSREF

44. Wands D, Hansen R, Taylor R. Causes of infantile acute liver failure in the west of scotland. J Pediatr Gastroenterol Nutr 2018;66 Suppl 2:823.
PUBMED | CROSSREF

45. Yankol Y, Ertugrul M, Kanmaz T, Mecit N, Ocak I, Durmaz O, et al. Management of pediatric acute liver failure in a region with insufficient deceased donor support: a single-center experience. Exp Clin Transplant 2016;14:535-41.
PUBMED

46. Squires JE, McKiernan P, Squires RH. Acute liver failure: an update. Clin Liver Dis 2018;22:773-805.
PUBMED | CROSSREF

47. Squires RH Jr. Acute liver failure in children. Semin Liver Dis 2008;28:153-66.
PUBMED | CROSSREF

48. Dhawan A. Etiology and prognosis of acute liver failure in children. Liver Transpl 2008;14 Suppl 2:S80-4.
PUBMED | CROSSREF

https://doi.org/10.5223/pghn.2020.23.6.501